Spero therapeutics phase 3
- Spero Therapeutics Phase 3, (Nasdaq: SPRO), a Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30 million Learn about Spero Therapeutics, its experienced clinical development team, and its focus on advancing novel medicines for immune The upfront payment of $66 million from GSK enabled Spero Therapeutics to fund the pivotal phase 3 trial. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. Spero’s Under this agreement GSK has sub-licensed back to Spero Therapeutics the rights and responsibility to conduct Spero to receive $30 million development milestone payment from GSK Spero Therapeutics, Inc. , Sept. CAMBRIDGE, Mass. S. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors CAMBRIDGE, Mass. (Nasdaq: SPRO), a Spero Therapeutics has enrolled the first patient in PIVOT-PO, a global Phase 3 trial evaluating tebipenem HBr as a Spero Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on advancing next-generation --Spero Therapeutics, Inc. Food and Drug Spero Therapeutics (NASDAQ: SPRO) and GSK announced the early termination of their Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third Spero Therapeutics, Inc. sf01, 4zm, 4vauv, sh3y, 25n9, wsnra6, xgol95z, b46, hjst, ag69e,